Artiva Biotherapeutics (ARTV) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Artiva Biotherapeutics (NASDAQ: ARTV) in the last few weeks:

• 5/8/2026 – Artiva Biotherapeutics had its price target raised by HC Wainwright from $15.00 to $35.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Artiva Biotherapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $18.00 price target on the stock.
• 4/28/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/24/2026 – Artiva Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Artiva Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/12/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/4/2026 – Artiva Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/11/2026 – Artiva Biotherapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $18.00 price target on the stock.

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.